Implication for transglutaminase 2-mediated activation of β-catenin signaling in neointimal vascular smooth muscle cells in chronic cardiac allograft rejection.
Implication for transglutaminase 2-mediated activation of β-catenin signaling in neointimal vascular smooth muscle cells in chronic cardiac allograft rejection.
复制标题
DOI:
10.1016/j.healun.2012.04.009
复制
发表时间:
2012-09
期刊:
影响因子:
--
通讯作者:
Nurminskaya M
中科院分区:
文献类型:
--
作者:
Beazley KE;Zhang T;Lima F;Pozharskaya T;Niger C;Tzitzikov E;Azimzadeh AM;Nurminskaya M
Cardiac allograft vasculopathy (CAV) remains the main cause of long-term transplant rejection. It is characterized by hyperproliferation of vascular smooth muscle cells (VSMCs). Canonical β-catenin signaling is a critical regulator of VSMC proliferation in development; however, the role of this pathway and its regulation in CAV progression are obscure. We investigated the activity of β-catenin signaling and the role for a putative activating ligand, transglutaminase 2 (TG2), in chronic cardiac rejection. Hearts from Bm12 mice were transplanted into C57BL/6 mice (Class II mismatch), and allografts were harvested 8 weeks after transplantation. Accumulation and sub-cellular distribution of β-catenin protein and expression of several components of β-catenin signaling were analyzed as hallmarks of pathway activation. In vitro, PDGF treatment was used to mimic the inflammatory milieu in VSMC and organotypic heart slice cultures. Activation of β-catenin in allografts compared to isografts or naïve hearts was evidenced by the augmented expression of β-catenin target genes, as well as the accumulation and nuclear localization of the β-catenin protein in VSMCs of the occluded allograft vessels. Expression of TG2, an activator of β-catenin signaling in VSMCs, was dramatically increased in allografts. Further, our ex vivo data demonstrate that TG2 is required for VSMC proliferation and for β-catenin activation by PDGF in cardiac tissue. β-catenin signaling is activated in occluded vessels in murine cardiac allografts. TG2 is implicated as an endogenous activator of this signaling pathway and may therefore have a role in the pathogenesis of CAV during chronic allograft rejection.
登录
查看更多内容
影响因子:
4.8
作者:
Abid, MR;Yano, K;Aird, WC
通讯作者:
Aird, WC
影响因子:
1.8
作者:
Cho, Byung-Ryul;Kim, Min-Kyung;Kim, Dae-Joong
通讯作者:
Kim, Dae-Joong
影响因子:
0.9
作者:
Lemstrom, K;Sihvola, R;Koskinen, P
通讯作者:
Koskinen, P
影响因子:
64.5
作者:
Inoki, Ken;Ouyang, Hongjiao;Guan, Kun-Liang
通讯作者:
Guan, Kun-Liang
影响因子:
--
作者:
Autieri, MV
通讯作者:
Autieri, MV